A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes

Munther Al-Momani; Muneer Ali Abu Alsamen; Eyas Al Mousa; Mohammad Ghnaimat; Fares Haddad; Mahmoud Hashim; Mohammad Jabary; Abdelkarim Khawaldeh; Taroub Khoury; Nadima Shegem; Mazen Matalka

doi:doi:10.11648/j.ijde.20220704.13

A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes

Munther Al-Momani, Muneer Ali Abu Alsamen, Eyas Al Mousa, Mohammad Ghnaimat, Fares Haddad, Mahmoud Hashim, Mohammad Jabary, Abdelkarim Khawaldeh, Taroub Khoury, Nadima Shegem, Mazen Matalka

Published in International Journal of Diabetes and Endocrinology (Volume 7, Issue 4)

Received: 3 November 2022 Accepted: 17 November 2022 Published: 23 November 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: The prevalence of type 2 diabetes (T2D) is increasing in Jordan and cardiovascular disease (CVD) is considered the leading cause of morbidity and mortality among patients with T2D patients. New data emerged with novel antihyperglycemic agents that demonstrated reduction in cardiorenal outcomes. Aims: The aims of the expert panel were to provide a multidisciplinary consensus approach to the screening, diagnosis, controlling cardiovascular risk factors, treatment, and monitoring of T2D. In addition, the panel’s aim was to develop an algorithm, incorporating new data to serve as an easy-to-use tool by health care providers (HCPs) to ultimately improve the decision-making process and outcome. Methods: A panel of experts from different specialties representing various medical societies met to discuss and review all the relevant T2D literature and the related international clinical practice guidelines on T2D. The panel evaluated and developed a comprehensive understanding of the current situation in Jordan, addressing the screening, diagnosis, pharmacological treatment, management, and monitoring parameters of T2D. Results: The expert panel established criteria for screening and diagnosis of patients with T2D driven by international clinical practice guidelines. The panel addressed all the cardiovascular (CV) risk factors associated with T2D and developed a risk stratification strategy. Accordingly, treatment recommendations were proposed based on the evidence of reduction of cardiorenal events and hospitalizations for heart failure (HFF) with the different options of pharmacological treatments. A treatment algorithm was drafted to provide guidance to the HCPs on the management of T2D. Conclusion: The focus of treatment in T2D has shifted from just controlling hyperglycemia towards reduction in cardio-renal complications. New data with two disease-modifying agents have changed the landscape of T2D treatment. It was important to develop a consensus statement with a multidisciplinary approach to provide HCPs with useful tools to use in the management of T2D, including a treatment algorithm. These recommendations would help increase awareness about the management of T2D in Jordan with the ultimate goal of improving cardiorenal outcomes.

Published in	International Journal of Diabetes and Endocrinology (Volume 7, Issue 4)
DOI	10.11648/j.ijde.20220704.13
Page(s)	122-136
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Type 2 Diabetes, Consensus Statement, Management, Jordan

References

[1]	World Health Organization. Global report on diabetes. Accessed 1/7/2022 https://www.who.int/publications/i/item/9789241565257
[2]	International Diabetes Federation. Facts and Figures. Accessed 1/7/2022 https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
[3]	International Diabetes Federation. Facts and Figures. Accessed 1/7/2022 https://diabetesatlas.org/data/en/region/4/mena.html
[4]	International Diabetes Federation. Facts and Figures. Accessed 1/7/2022 https://diabetesatlas.org/data/en/country/102/jo.html
[5]	Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 1982; 21: 730-738.
[6]	Wingard DL, Barrett-Connor EL. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Rieber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 1995: 429-48. (NIH publication no. 95-1468.).
[7]	Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291-1297.
[8]	The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 2010; 375: 2215–2222.
[9]	Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. The New England Journal of Medicine. 2017; 376: 1407–1418.
[10]	Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. Advances in Chronic Kidney Disease. 2018; 25: 121–132.
[11]	Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. Journal of the American Society of Nephrology. 2013; 24: 302–308.
[12]	Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab. 2020 Sep; 22 (9): 1607-1618. doi: 10.1111/dom.14074. Epub 2020 Jun 3.
[13]	Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20 (5): 853–72.
[14]	Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death. Circulation. 2015; 132 (10): 923–31.
[15]	Faden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, Di Lenarda A, Faggiano P, Cioffi G. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013; 101: 309-316; 2.
[16]	Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Cardiac Fail. 2021; 27 (4): 387–413.
[17]	Haddad JA, Al Hyari MA, Al Momani MS, et al. Baseline characteristics and treatment pattern of type 2 diabetes patients in Jordan: analysis from the DISCOVER patient population. Alexandria Journal of Medicine 2020, VOL. 56, NO. 1, 51–55 https://doi.org/10.1080/20905068.2020.1747733
[18]	Hammoudeh AJ, Tabbalat R, Alhaddad IA, Khader Y, Jarrah M, Izraiq M, Al-Mousa E. Short- and long-term outcomes in Middle Eastern diabetic patients after percutaneous coronary intervention: results from The First Jordanian PCI Registry (JoPCR1) Diabetol Int. 2016 May 3; 8 (1): 30-38. doi: 10.1007/s13340-016-0273-z. eCollection 2017 Mar.
[19]	Hammoudeh AJ, Al-Tarawneh H, Elharassis A, Haddad J, Mahadeen Z, Badran N, Izraiq M, Al-Mousa E. Prevalence of conventional risk factors in Jordanians with coronary heart disease: the Jordan Hyperlipidemia and Related Targets Study (JoHARTS). Int J Cardiol 2006 Jun 16; 110 (2): 179-83. doi: 10.1016/j.ijcard.2005.08.005.
[20]	US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Aug 24; 326 (8): 736-743. doi: 10.1001/jama.2021.12531.
[21]	Abu Hijleh OM, Annabi F, Abujbara M, Alkhawaldeh A, Haddad F, Haddad J, Alhyari M, Howlett H, Jarrah N, Shegem N, Al-Naqshbandi1 M. The National Jordanian Experts Consensus on Diagnosis and Treatment of Prediabetes. International Journal of Diabetes and Endocrinology 2021; 6 (1): 46-53.
[22]	Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14 (2): 88-98. doi: 10.1038/nrendo.2017.151.
[23]	Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017; 102 (10): 3848-3857. doi: 10.1210/jc.2017-01354.
[24]	American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022 Diabetes Care 2022; 45 (Suppl. 1): S17–S38 \| https://doi.org/10.2337/dc22-S002.
[25]	Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009; 53 (5 Suppl): S35–42.
[26]	Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence Diabetes Ther from across the world in 2007–2017. Cardiovasc Diabetol. 2018; 17 (1): 83.
[27]	American Diabetes Association. 12. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45 (Supplement_1): S144–S174.
[28]	Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310 (6): 356–60.
[29]	Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016; 129 (2): 153-162. e7.
[30]	American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan 1; 43 (Supplement 1): S135–51.
[31]	Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41 (2): 255–323.
[32]	Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136 (6): e137-e61.
[33]	Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–117.
[34]	UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865.
[35]	American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45 (Suppl. 1): S83–S96.
[36]	Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Jan; 26 (1): 107-139. doi: 10.4158/CS-2019-0472.
[37]	Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e1082–e1143. doi: 10.1161/CIR.0000000000000625.
[38]	Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 138: e426–e483. doi: 10.1161/CIR.0000000000000597.
[39]	American Diabetes Association. 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2021, Diabetes Care 44 (2021) S53–S72.
[40]	Zhang Y, Pan XF, Chen J, Xia L, Cao A, Zhang Y, Pan A. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies, Diabetologia 63 (2020) 21–33.
[41]	Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247–2257. doi: 10.1056/NEJMoa1509225.
[42]	Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311–322. doi: 10.1056/NEJMoa1603827.
[43]	Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 839–848. doi: 10.1056/NEJMoa1616011.
[44]	Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834–1844. doi: 10.1056/NEJMoa1607141.
[45]	Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381: 841–851. doi: 10.1056/NEJMoa1901118.
[46]	Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 1228–1239. doi: 10.1056/NEJMoa1612917.
[47]	Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, et al; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet. 2018; 392: 1519–1529. doi: 10.1016/S0140-6736(18)32261-X.
[48]	Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121–130. doi: 10.1016/S0140-6736(19)31149-3.
[49]	Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, et al; AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385: 896–907. doi: 10.1056/NEJMoa2108269.
[50]	Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal Net al; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018; 6: 105–113. doi: 10.1016/S2213-8587(17)30412-6.
[51]	Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139: 2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
[52]	FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes. May 22, 2022.
[53]	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). https://clinicaltrials.gov/ct2/show/NCT04255433
[54]	Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–2128. doi: 10.1056/NEJMoa1504720.
[55]	Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPAREG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–334. doi: 10.1056/NEJMoa1515920.
[56]	Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644–657. doi: 10.1056/NEJMoa1611925.
[57]	Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–357. doi: 10.1056/NEJMoa1812389.
[58]	Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020; 383: 1425–1435. doi: 10.1056/NEJMoa2004967.
[59]	Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021; 384: 129–139. doi: 10.1056/NEJMoa2030186.
[60]	McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995–2008. doi: 10.1056/NEJMoa1911303.
[61]	Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al; EMPEROR Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413–1424. doi: 10.1056/NEJMoa2022190.
[62]	Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384: 117–128. doi: 10.1056/NEJMoa2030183.
[63]	Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-61.
[64]	Solomon SD, McMurray JJV, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2206286.
[65]	Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295–2306. doi: 10.1056/NEJMoa1811744.
[66]	Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–1446. doi: 10.1056/NEJMoa2024816.
[67]	American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 Diabetes Care 2022; 45 (Suppl. 1): S125–S143 \| https://doi.org/10.2337/dc22-S009
[68]	Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire M, Morris PB, Neumiller JJ, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020; 76: 1117–1145. doi: 10.1016/j.jacc.2020.05.037.
[69]	Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, Knight C, Levi M, Rasouli N, and Richardson CR. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care dci220014 https://doi.org/10.2337/dci22-0014
[70]	Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone J, Buse JB, Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 41 (2018) 2669–2701.
[71]	Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Buse JB, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia 61 (2018) 2461–2498.
[72]	Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, Davies MJ, 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia 63 (2020) 221–228.
[73]	U. K. P. D. S. Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 352 (1998) 854–865.
[74]	Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z.. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019 Jul 30; 18 (1): 96. doi: 10.1186/s12933-019-0900-7.
[75]	Griffin SJ, Leaver JK, Irving GJ, Impact of metformin on cardiovascular disease: a meta-analysis of randomized trials among people with type 2 diabetes, Diabetologia 60 (2017) 1620–1629.
[76]	Goldberg RB, Orchard TJ, Crandall JP, Boyko EJ, Budoff M, Dabelea D, Gadde KM, Knowler WC, Lee CG, Nathan DM, Watson K, Temprosa M and on behalf of the Diabetes Prevention Program Research Group. Circulation. 2022 May 31; 145 (22): 1632-1641. doi: 10.1161/CIRCULATIONAHA.121.056756. Epub 2022 May 23.
[77]	Kirpichnikov D, McFarlane SI, Sowers JR, Metformin: an update, Ann. Intern. Med. 137 (2002) 25–33.
[78]	Seidu S, Cos X, Brunton S, et al 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care Prim Care Diabetes 2022 Apr; 16 (2): 223-244. doi: 10.1016/j.pcd.2022.02.002. Epub 2022 Feb 16.
[79]	Tang Y, Weiss T, Liu J, Rajpathak S, Khunti K, Metformin adherence and discontinuation among patients with type 2 diabetes: a retrospective cohort study, J. Clin. Transl. Endocrinol. 20 (2020), 100225.
[80]	Tarry-Adkins JL, Grant ID, Ozanne SE, Reynolds RM, Aiken CE, Efficacy and side effect profile of different formulations of metformin: a systematic review and meta-analysis, Diabetes Ther. 12 (2021) 1901–1914.
[81]	Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M; VERIFY study group. Glycemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicenter, randomized, double-blind trial. Lancet 2019; 394: 1519–1529.
[82]	Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Agrusta M, Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomized, multicenter trial, Lancet Diabetes Endocrinol. 5 (2017) 887–897.
[83]	Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Latini R, Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes, Eur. J. Heart Fail. 20 (2018) 888–895.
[84]	Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, Day RO, Metformin therapy in patients with chronic kidney disease, Diabetes Obes. Metab. 14 (2012) 963–965.
[85]	Davies M, Chatterjee S, Khunti K, The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies, Clin. Pharmacol. 8 (2016) 61–81.
[86]	Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes 2022 Apr; 16 (2): 223-244. doi: 10.1016/j.pcd.2022.02.002. Epub 2022 Feb 16.
[87]	Engelhardt K, Ferguson M, Rosselli JL, Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors, Ann. Pharmacother. 55 (2021) 543–548.
[88]	Siaw, M. Y. L. and J. Y. Lee, Multidisciplinary collaborative care in the management of patients with uncontrolled diabetes: A systematic review and meta-analysis. Int J Clin Pract, 2019. 73 (2): p. e13288.
[89]	Gómez-Velasco DV, Almeda-Valdes P, Martagón AJ, Galán-Ramírez GA, and Aguilar-Salinas CA. Empowerment of patients with type 2 diabetes: current perspectives. Diabetes Metab Syndr Obes. 2019; 12: 1311–1321.

Cite This Article

Plain Text BibTeX RIS

APA Style

Munther Al-Momani, Muneer Ali Abu Alsamen, Eyas Al Mousa, Mohammad Ghnaimat, Fares Haddad, et al. (2022). A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes. International Journal of Diabetes and Endocrinology, 7(4), 122-136. https://doi.org/10.11648/j.ijde.20220704.13

Copy | Download

ACS Style

Munther Al-Momani; Muneer Ali Abu Alsamen; Eyas Al Mousa; Mohammad Ghnaimat; Fares Haddad, et al. A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes. Int. J. Diabetes Endocrinol. 2022, 7(4), 122-136. doi: 10.11648/j.ijde.20220704.13

Copy | Download

AMA Style

Munther Al-Momani, Muneer Ali Abu Alsamen, Eyas Al Mousa, Mohammad Ghnaimat, Fares Haddad, et al. A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes. Int J Diabetes Endocrinol. 2022;7(4):122-136. doi: 10.11648/j.ijde.20220704.13

Copy | Download

@article{10.11648/j.ijde.20220704.13,
  author = {Munther Al-Momani and Muneer Ali Abu Alsamen and Eyas Al Mousa and Mohammad Ghnaimat and Fares Haddad and Mahmoud Hashim and Mohammad Jabary and Abdelkarim Khawaldeh and Taroub Khoury and Nadima Shegem and Mazen Matalka},
  title = {A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {7},
  number = {4},
  pages = {122-136},
  doi = {10.11648/j.ijde.20220704.13},
  url = {https://doi.org/10.11648/j.ijde.20220704.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220704.13},
  abstract = {Background: The prevalence of type 2 diabetes (T2D) is increasing in Jordan and cardiovascular disease (CVD) is considered the leading cause of morbidity and mortality among patients with T2D patients. New data emerged with novel antihyperglycemic agents that demonstrated reduction in cardiorenal outcomes. Aims: The aims of the expert panel were to provide a multidisciplinary consensus approach to the screening, diagnosis, controlling cardiovascular risk factors, treatment, and monitoring of T2D. In addition, the panel’s aim was to develop an algorithm, incorporating new data to serve as an easy-to-use tool by health care providers (HCPs) to ultimately improve the decision-making process and outcome. Methods: A panel of experts from different specialties representing various medical societies met to discuss and review all the relevant T2D literature and the related international clinical practice guidelines on T2D. The panel evaluated and developed a comprehensive understanding of the current situation in Jordan, addressing the screening, diagnosis, pharmacological treatment, management, and monitoring parameters of T2D. Results: The expert panel established criteria for screening and diagnosis of patients with T2D driven by international clinical practice guidelines. The panel addressed all the cardiovascular (CV) risk factors associated with T2D and developed a risk stratification strategy. Accordingly, treatment recommendations were proposed based on the evidence of reduction of cardiorenal events and hospitalizations for heart failure (HFF) with the different options of pharmacological treatments. A treatment algorithm was drafted to provide guidance to the HCPs on the management of T2D. Conclusion: The focus of treatment in T2D has shifted from just controlling hyperglycemia towards reduction in cardio-renal complications. New data with two disease-modifying agents have changed the landscape of T2D treatment. It was important to develop a consensus statement with a multidisciplinary approach to provide HCPs with useful tools to use in the management of T2D, including a treatment algorithm. These recommendations would help increase awareness about the management of T2D in Jordan with the ultimate goal of improving cardiorenal outcomes.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes
AU  - Munther Al-Momani
AU  - Muneer Ali Abu Alsamen
AU  - Eyas Al Mousa
AU  - Mohammad Ghnaimat
AU  - Fares Haddad
AU  - Mahmoud Hashim
AU  - Mohammad Jabary
AU  - Abdelkarim Khawaldeh
AU  - Taroub Khoury
AU  - Nadima Shegem
AU  - Mazen Matalka
Y1  - 2022/11/23
PY  - 2022
N1  - https://doi.org/10.11648/j.ijde.20220704.13
DO  - 10.11648/j.ijde.20220704.13
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 122
EP  - 136
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20220704.13
AB  - Background: The prevalence of type 2 diabetes (T2D) is increasing in Jordan and cardiovascular disease (CVD) is considered the leading cause of morbidity and mortality among patients with T2D patients. New data emerged with novel antihyperglycemic agents that demonstrated reduction in cardiorenal outcomes. Aims: The aims of the expert panel were to provide a multidisciplinary consensus approach to the screening, diagnosis, controlling cardiovascular risk factors, treatment, and monitoring of T2D. In addition, the panel’s aim was to develop an algorithm, incorporating new data to serve as an easy-to-use tool by health care providers (HCPs) to ultimately improve the decision-making process and outcome. Methods: A panel of experts from different specialties representing various medical societies met to discuss and review all the relevant T2D literature and the related international clinical practice guidelines on T2D. The panel evaluated and developed a comprehensive understanding of the current situation in Jordan, addressing the screening, diagnosis, pharmacological treatment, management, and monitoring parameters of T2D. Results: The expert panel established criteria for screening and diagnosis of patients with T2D driven by international clinical practice guidelines. The panel addressed all the cardiovascular (CV) risk factors associated with T2D and developed a risk stratification strategy. Accordingly, treatment recommendations were proposed based on the evidence of reduction of cardiorenal events and hospitalizations for heart failure (HFF) with the different options of pharmacological treatments. A treatment algorithm was drafted to provide guidance to the HCPs on the management of T2D. Conclusion: The focus of treatment in T2D has shifted from just controlling hyperglycemia towards reduction in cardio-renal complications. New data with two disease-modifying agents have changed the landscape of T2D treatment. It was important to develop a consensus statement with a multidisciplinary approach to provide HCPs with useful tools to use in the management of T2D, including a treatment algorithm. These recommendations would help increase awareness about the management of T2D in Jordan with the ultimate goal of improving cardiorenal outcomes.
VL  - 7
IS  - 4
ER  -

Copy | Download

Author Information

Munther Al-Momani

Endocrinology Private Clinic and Al Khalidi Hospital and Medical Center, The Jordanian Society of Endocrinology, Diabetes & Metabolism, Amman, Jordan
Muneer Ali Abu Alsamen

General Practice Private Clinic, The Jordanian General Practitioner Society, Amman, Jordan
Eyas Al Mousa

Cardiology Private Clinic and Istishari Hospital, Jordan Cardiac Society, Amman, Jordan
Mohammad Ghnaimat

Nephrology Private Clinic, Jordan Society of Nephrology, Renal Transplantation and the Jordanian Society of Internal Medicine, Amman, Jordan
Fares Haddad

Endocrinology, Abdali Medical Center, The Jordanian Society of Endocrinology, Diabetes & Metabolism, Amman, Jordan
Mahmoud Hashim

General Practice Private Clinic, The Jordanian General Practitioner Society, Amman, Jordan
Mohammad Jabary

Cardiology Private Clinic, Jordan Cardiac Society, Amman, Jordan
Abdelkarim Khawaldeh

Endocrinology Private Clinic, The Jordanian Society of Endocrinology, Diabetes & Metabolism, Amman, Jordan
Taroub Khoury

Internal Medicine Private Clinic, The Jordanian Society of Internal Medicine, Amman, Jordan
Nadima Shegem

Endocrinology Private Clinic, The Jordanian Society for the Care of Diabetes, Amman, Jordan
Mazen Matalka

Clinical Research, Advanced Healthcare Solutions Contract Research Organization, Amman, Jordan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Munther Al-Momani, Muneer Ali Abu Alsamen, Eyas Al Mousa, Mohammad Ghnaimat, Fares Haddad, et al. (2022). A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes. International Journal of Diabetes and Endocrinology, 7(4), 122-136. https://doi.org/10.11648/j.ijde.20220704.13

Copy | Download

ACS Style

Munther Al-Momani; Muneer Ali Abu Alsamen; Eyas Al Mousa; Mohammad Ghnaimat; Fares Haddad, et al. A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes. Int. J. Diabetes Endocrinol. 2022, 7(4), 122-136. doi: 10.11648/j.ijde.20220704.13

Copy | Download

AMA Style

Munther Al-Momani, Muneer Ali Abu Alsamen, Eyas Al Mousa, Mohammad Ghnaimat, Fares Haddad, et al. A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes. Int J Diabetes Endocrinol. 2022;7(4):122-136. doi: 10.11648/j.ijde.20220704.13

Copy | Download

@article{10.11648/j.ijde.20220704.13,
  author = {Munther Al-Momani and Muneer Ali Abu Alsamen and Eyas Al Mousa and Mohammad Ghnaimat and Fares Haddad and Mahmoud Hashim and Mohammad Jabary and Abdelkarim Khawaldeh and Taroub Khoury and Nadima Shegem and Mazen Matalka},
  title = {A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {7},
  number = {4},
  pages = {122-136},
  doi = {10.11648/j.ijde.20220704.13},
  url = {https://doi.org/10.11648/j.ijde.20220704.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220704.13},
  abstract = {Background: The prevalence of type 2 diabetes (T2D) is increasing in Jordan and cardiovascular disease (CVD) is considered the leading cause of morbidity and mortality among patients with T2D patients. New data emerged with novel antihyperglycemic agents that demonstrated reduction in cardiorenal outcomes. Aims: The aims of the expert panel were to provide a multidisciplinary consensus approach to the screening, diagnosis, controlling cardiovascular risk factors, treatment, and monitoring of T2D. In addition, the panel’s aim was to develop an algorithm, incorporating new data to serve as an easy-to-use tool by health care providers (HCPs) to ultimately improve the decision-making process and outcome. Methods: A panel of experts from different specialties representing various medical societies met to discuss and review all the relevant T2D literature and the related international clinical practice guidelines on T2D. The panel evaluated and developed a comprehensive understanding of the current situation in Jordan, addressing the screening, diagnosis, pharmacological treatment, management, and monitoring parameters of T2D. Results: The expert panel established criteria for screening and diagnosis of patients with T2D driven by international clinical practice guidelines. The panel addressed all the cardiovascular (CV) risk factors associated with T2D and developed a risk stratification strategy. Accordingly, treatment recommendations were proposed based on the evidence of reduction of cardiorenal events and hospitalizations for heart failure (HFF) with the different options of pharmacological treatments. A treatment algorithm was drafted to provide guidance to the HCPs on the management of T2D. Conclusion: The focus of treatment in T2D has shifted from just controlling hyperglycemia towards reduction in cardio-renal complications. New data with two disease-modifying agents have changed the landscape of T2D treatment. It was important to develop a consensus statement with a multidisciplinary approach to provide HCPs with useful tools to use in the management of T2D, including a treatment algorithm. These recommendations would help increase awareness about the management of T2D in Jordan with the ultimate goal of improving cardiorenal outcomes.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - A Jordanian Multidisciplinary Consensus Statement on the Management of Type 2 Diabetes
AU  - Munther Al-Momani
AU  - Muneer Ali Abu Alsamen
AU  - Eyas Al Mousa
AU  - Mohammad Ghnaimat
AU  - Fares Haddad
AU  - Mahmoud Hashim
AU  - Mohammad Jabary
AU  - Abdelkarim Khawaldeh
AU  - Taroub Khoury
AU  - Nadima Shegem
AU  - Mazen Matalka
Y1  - 2022/11/23
PY  - 2022
N1  - https://doi.org/10.11648/j.ijde.20220704.13
DO  - 10.11648/j.ijde.20220704.13
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 122
EP  - 136
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20220704.13
AB  - Background: The prevalence of type 2 diabetes (T2D) is increasing in Jordan and cardiovascular disease (CVD) is considered the leading cause of morbidity and mortality among patients with T2D patients. New data emerged with novel antihyperglycemic agents that demonstrated reduction in cardiorenal outcomes. Aims: The aims of the expert panel were to provide a multidisciplinary consensus approach to the screening, diagnosis, controlling cardiovascular risk factors, treatment, and monitoring of T2D. In addition, the panel’s aim was to develop an algorithm, incorporating new data to serve as an easy-to-use tool by health care providers (HCPs) to ultimately improve the decision-making process and outcome. Methods: A panel of experts from different specialties representing various medical societies met to discuss and review all the relevant T2D literature and the related international clinical practice guidelines on T2D. The panel evaluated and developed a comprehensive understanding of the current situation in Jordan, addressing the screening, diagnosis, pharmacological treatment, management, and monitoring parameters of T2D. Results: The expert panel established criteria for screening and diagnosis of patients with T2D driven by international clinical practice guidelines. The panel addressed all the cardiovascular (CV) risk factors associated with T2D and developed a risk stratification strategy. Accordingly, treatment recommendations were proposed based on the evidence of reduction of cardiorenal events and hospitalizations for heart failure (HFF) with the different options of pharmacological treatments. A treatment algorithm was drafted to provide guidance to the HCPs on the management of T2D. Conclusion: The focus of treatment in T2D has shifted from just controlling hyperglycemia towards reduction in cardio-renal complications. New data with two disease-modifying agents have changed the landscape of T2D treatment. It was important to develop a consensus statement with a multidisciplinary approach to provide HCPs with useful tools to use in the management of T2D, including a treatment algorithm. These recommendations would help increase awareness about the management of T2D in Jordan with the ultimate goal of improving cardiorenal outcomes.
VL  - 7
IS  - 4
ER  -

Copy | Download